Jochems et al. analyzed the transcriptome and senolytic responses induced by Navitolax (ABT-263), an orally bioavailable anti-apoptotic Bcl-2 inhibitor, in a panel of 13 cancer cell lines rendered senescent and found that the composition of the SASP is more influenced by the cell of origin rather than by the senescence trigger. This evidence concerns the gene BCL2 and cancer.